Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2015 (2015), Article ID 325851, 11 pages
http://dx.doi.org/10.1155/2015/325851
Research Article

Metformin Treatment in Type 2 Diabetes in Pregnancy: An Active Controlled, Parallel-Group, Randomized, Open Label Study in Patients with Type 2 Diabetes in Pregnancy

1Department of Obstetrics and Gynecology, Dow University of Health Sciences, Karachi 74400, Pakistan
2Department of Pharmacology, Medical and Dental College, Bahria University, Karachi 75500, Pakistan
3School of Public Health, Dow University of Health Sciences, Karachi 75300, Pakistan
4Department of Community Health Sciences, United Medical and Dental College, Karachi 74900, Pakistan
5Department of Obstetrics and Gynecology, Hamdard University Hospital, Karachi 74400, Pakistan

Received 14 December 2014; Revised 12 February 2015; Accepted 20 February 2015

Academic Editor: Vipin Gupta

Copyright © 2015 Jahan Ara Ainuddin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Aims. To assess the effect of metformin and to compare it with insulin treatment in patients with type 2 diabetes in pregnancy in terms of perinatal outcome, maternal complications, additional insulin requirement, and treatment acceptability. Methods. In this randomized, open label study, 206 patients with type 2 diabetes in pregnancy who met the eligibility criteria were selected from the antenatal clinics. Insulin was added to metformin treatment when required, to maintain the target glycemic control. The patients were followed up till delivery. Maternal, and perinatal outcomes and pharmacotherapeutic characteristics were recorded on a proforma. Results. Maternal characteristics were comparable in metformin and insulin treated group. 84.9% patients in metformin group required add-on insulin therapy at mean gestational age of 26.58 ± 3.85 weeks. Less maternal weight gain and pregnancy induced hypertension were observed in metformin treated group. Small for date babies were more in metformin group . Neonatal hypoglycemia was significantly less and so was NICU stay of >24 hours in metformin group . Significant reduction in cost of treatment was found in metformin group. Conclusion. Metformin alone or with add-on insulin is an effective and cheap treatment option for patients with type 2 diabetes in pregnancy. This trial is registered with clinical trial registration number: Clinical trials.gov NCT01855763.